BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with ...
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO® (berotralstat) leading to a
United States H James Wedner Bryan Arnold John Bluth Anaheim Convention Center Biocryst Pharmaceuticals
Source: eagletribune.com